Reduced Bone Mass and Increased Osteocyte Tartrate-Resistant Acid Phosphatase (TRAP) Activity, But Not Low Mineralized Matrix Around Osteocyte Lacunae, Are Restored After Recovery From Exogenous Hyperthyroidism in Male Mice.
BONE MINERALIZATION
HYPERTHYROIDISM
OSTEOCYTES
OSTEOCYTIC OSTEOLYSIS
SECONDARY OSTEOPOROSIS
Journal
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
ISSN: 1523-4681
Titre abrégé: J Bone Miner Res
Pays: United States
ID NLM: 8610640
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
28
10
2022
received:
03
06
2022
accepted:
01
11
2022
pubmed:
5
11
2022
medline:
10
1
2023
entrez:
4
11
2022
Statut:
ppublish
Résumé
Hyperthyroidism causes secondary osteoporosis through favoring bone resorption over bone formation, leading to bone loss with elevated bone fragility. Osteocytes that reside within lacunae inside the mineralized bone matrix orchestrate the process of bone remodeling and can themselves actively resorb bone upon certain stimuli. Nevertheless, the interaction between thyroid hormones and osteocytes and the impact of hyperthyroidism on osteocyte cell function are still unknown. In a preliminary study, we analyzed bones from male C57BL/6 mice with drug-induced hyperthyroidism, which led to mild osteocytic osteolysis with 1.14-fold larger osteocyte lacunae and by 108.33% higher tartrate-resistant acid phosphatase (TRAP) activity in osteocytes of hyperthyroid mice compared to euthyroid mice. To test whether hyperthyroidism-induced bone changes are reversible, we rendered male mice hyperthyroid by adding levothyroxine into their drinking water for 4 weeks, followed by a weaning period of 4 weeks with access to normal drinking water. Hyperthyroid mice displayed cortical and trabecular bone loss due to high bone turnover, which recovered with weaning. Although canalicular number and osteocyte lacunar area were similar in euthyroid, hyperthyroid and weaned mice, the number of terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL)-positive osteocytes was 100% lower in the weaning group compared to euthyroid mice and the osteocytic TRAP activity was eightfold higher in hyperthyroid animals. The latter, along with a 3.75% lower average mineralization around the osteocyte lacunae in trabecular bone, suggests osteocytic osteolysis activity that, however, did not result in significantly enlarged osteocyte lacunae. In conclusion, we show a recovery of bone microarchitecture and turnover after reversal of hyperthyroidism to a euthyroid state. In contrast, osteocytic osteolysis was initiated in hyperthyroidism, but its effects were not reversed after 4 weeks of weaning. Due to the vast number of osteocytes in bone, we speculate that even minor individual cell functions might contribute to altered bone quality and mineral homeostasis in the setting of hyperthyroidism-induced bone disease. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Substances chimiques
Tartrate-Resistant Acid Phosphatase
EC 3.1.3.2
Drinking Water
0
Minerals
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
131-143Informations de copyright
© 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Références
Ebeling PR, Hanh HN, Aleksova J, Vincent AJ, Wong P, Milat F. Secondary osteoporosis. Endocr Rev. 2022;43(2):240-313.
Painter SE, Kleerekoper M, Camacho PM. Secondary osteoporosis: a review of the recent evidence. Endocr Pract. 2006;12(4):436-445.
Hofbauer LC, Hamann C, Ebeling PR. Approach to the patient with secondary osteoporosis. Eur J Endocrinol. 2010;162(6):1009-1020.
Gogakos AI, Duncan Bassett JH, Williams GR. Thyroid and bone. Arch Biochem Biophys. 2010;503(1):129-136. https://doi.org/10.1016/j.abb.2010.06.021.
Williams GR, Bassett JHD. Thyroid diseases and bone health. J Endocrinol Invest. 2018;41(1):99-109.
Duncan Bassett JH, Williams GR. Role of thyroid hormones in skeletal development and bone maintenance. Endocr Rev. 2016;37(2):135-187.
Gouveia CH, Schultz JJ, Bianco AC, Brent GA. Thyroid hormone stimulation of osteocalcin gene expression in ROS 17/2.8 cells is mediated by transcriptional and post-transcriptional mechanisms. J Endocrinol. 2001;170(3):667-675.
Varga F, Rumpler M, Luegmayr E, Fratzl-Zelman N, Glantschnig H, Klaushofer K. Triiodothyronine, a regulator of osteoblastic differentiation: depression of histone H4, attenuation of c-fos/c-jun, and induction of osteocalcin expression. Calcif Tissue Int. 1997;61(5):404-411.
Banovac K, Koren E. Triiodothyronine stimulates the release of membrane-bound alkaline phosphatase in osteoblastic cells. Calcif Tissue Int. 2000;67(6):460-465.
Miura M, Tanaka K, Komatsu Y, et al. A novel interaction between thyroid hormones and 1,25(OH)2D3 in osteoclast formation. Biochem Biophys Res Commun. 2002;291(4):987-994.
Lademann F, Tsourdi E, Rijntjes E, et al. Lack of the thyroid hormone transporter Mct8 in osteoblast and osteoclast progenitors increases trabecular bone in male mice. Thyroid. 2020;30(2):329-342.
Tsourdi E, Rijntjes E, Köhrle J, Hofbauer LC, Rauner M. Hyperthyroidism and hypothyroidism in male mice and their effects on bone mass, bone turnover, and the Wnt inhibitors sclerostin and dickkopf-1. Endocrinology. 2015;156(10):3517-3527.
Tsourdi E, Lademann F, Ominsky MS, et al. Sclerostin blockade and zoledronic acid improve bone mass and strength in male mice with exogenous hyperthyroidism. Endocrinology. 2017;158(11):3765-3777.
Buenzli PR, Sims NA. Quantifying the osteocyte network in the human skeleton. Bone. 2015;75:144-150.
Plotkin LI, Gortazar AR, Davis HM, et al. Inhibition of osteocyte apoptosis prevents the increase in osteocytic receptor activator of nuclear factor kappa-beta ligand (RANKL) but does not stop bone resorption or the loss of bone induced by unloading. J Biol Chem. 2015;290(31):18934-18942.
Milovanovic P, Zimmermann EA, Hahn M, et al. Osteocytic canalicular networks: morphological implications for altered mechanosensitivity. ACS Nano. 2013;7(9):7542-7551.
Qing H, Ardeshirpour L, Divieti Pajevic P, et al. Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. J Bone Miner Res. 2012;27(5):1018-1029.
Tsourdi E, Jähn K, Rauner M, Busse B, Bonewald LF. Physiological and pathological osteocytic osteolysis. J Musculoskeletal Neuronal Interact. 2018;18(3):292-303.
Vahidi G, Rux C, Sherk VD, Heveran CM. Lacunar-canalicular bone remodeling: Impacts on bone quality and tools for assessment. Bone. 2021;143:115663.
Monfoulet LE, Rabier B, Dacquin R, et al. Thyroid hormone receptor β mediates thyroid hormone effects on bone remodeling and bone mass. J Bone Miner Res. 2011;26(9):2036-2044.
Derkx P, Birkenhäger-Frenkel DH. A thionin stain for visualizing bone cells, mineralizing fronts and cement lines in undecalcified bone sections. Biotech Histochem. 1995;70(2):70-74.
Jáuregui EJ, Akil O, Acevedo C, et al. Parallel mechanisms suppress cochlear bone remodeling to protect hearing. Bone. 2016;89:7-15.
Busse B, Hahn M, Soltau M, et al. Increased calcium content and inhomogeneity of mineralization render bone toughness in osteoporosis: mineralization, morphology and biomechanics of human single trabeculae. Bone. 2009;45(6):1034-1043.
Hemmatian H, Laurent MR, Ghazanfari S, et al. Accuracy and reproducibility of mouse cortical bone microporosity as quantified by desktop microcomputed tomography. PLoS One. 2017;12(8):e0182996.
Jähn K, Kelkar S, Zhao H, et al. Osteocytes acidify their microenvironment in response to PTHrP in vitro and in lactating mice in vivo. J Bone Miner Res. 2017;32(8):1761-1772.
Halleen JM, Alatalo SL, Suominen H, Cheng S. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res. 2000;15(7):1337-1345.
Bianco P, Ballanti P, Bonucci E. Tartrate-resistant acid phosphatase activity in rat osteoblasts and osteocytes. Calcif Tissue Int. 1988;43(3):167-171.
Bayley TA, Harrison JE, Mcneill KG, John R. Effect of thyrotoxicosis and its treatment on bone mineral and muscle mass. J Clin Endocrinol Metab. 1980;50(5):916-922.
Langdahl B, Loft AGR, Eriksen EF, Mosekilde L, Charles P. Bone mass, bone turnover and body composition in former hypothyroid patients receiving replacement therapy. Eur J Endocrinol. 1996;134(6):702-709.
Vestergaard P, Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk-a meta-analysis. Thyroid. 2003;13(6):585-593.
Cummings S, Nevitt M, Browner W, et al. Risk factors for hip fracture in white women. N Engl J Med. 1995;332(12):767-773.
Garnero P, Vassy V, Bertholin A, Riou JP. Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab. 1994;78(4):955-959.
Dole NS, Mazur CM, Acevedo C, et al. Osteocyte-intrinsic TGF-b signaling regulates bone article osteocyte-intrinsic TGF-b signaling regulates bone quality through perilacunar/canalicular remodeling. Cell Rep. 2017;21(9):2585-2596.
Tang S, Herber R-P, Ho S, Alliston T. Matrix metalloproteinase-13 is required for osteocytic perilacunar remodeling and maintains bone fracture resistance. J Bone Miner Res. 2012;27(9):1936-1950.
Parfitt AM. The cellular basis of bone turnover and bone loss a rebuttal of the osteocytic resorption-bone flow theory. Clin Orthop Relat Res. 1977;127:236-247.
Kerschnitzki M, Kollmannsberger P, Burghammer M, et al. Architecture of the osteocyte network correlates with bone material quality. J Bone Miner Res. 2013;28(8):1837-1845.
Stachnik K, Warmer M, Mohacsi I, et al. Multimodal X-ray imaging of nanocontainer-treated macrophages and calcium distribution in the perilacunar bone matrix. Sci Rep. 2020;10(1):1784.